These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37853119)

  • 1. Antiviral type III CRISPR signalling via conjugation of ATP and SAM.
    Chi H; Hoikkala V; Grüschow S; Graham S; Shirran S; White MF
    Nature; 2023 Oct; 622(7984):826-833. PubMed ID: 37853119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA processing by the CRISPR-associated NYN ribonuclease.
    Chi H; White MF
    Biochem J; 2024 Jun; 481(12):793-804. PubMed ID: 38785320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CRISPR antiphage defence mediated by the cyclic nucleotide-binding membrane protein Csx23.
    Grüschow S; McQuarrie S; Ackermann K; McMahon S; Bode BE; Gloster TM; White MF
    Nucleic Acids Res; 2024 Apr; 52(6):2761-2775. PubMed ID: 38471818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetramerisation of the CRISPR ring nuclease Crn3/Csx3 facilitates cyclic oligoadenylate cleavage.
    Athukoralage JS; McQuarrie S; Grüschow S; Graham S; Gloster TM; White MF
    Elife; 2020 Jun; 9():. PubMed ID: 32597755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Csx3 is a cyclic oligonucleotide phosphodiesterase associated with type III CRISPR-Cas that degrades the second messenger cA
    Brown S; Gauvin CC; Charbonneau AA; Burman N; Lawrence CM
    J Biol Chem; 2020 Oct; 295(44):14963-14972. PubMed ID: 32826317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis of cyclic oligoadenylate degradation by ancillary Type III CRISPR-Cas ring nucleases.
    Molina R; Jensen ALG; Marchena-Hurtado J; López-Méndez B; Stella S; Montoya G
    Nucleic Acids Res; 2021 Dec; 49(21):12577-12590. PubMed ID: 34850143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ring nucleases deactivate type III CRISPR ribonucleases by degrading cyclic oligoadenylate.
    Athukoralage JS; Rouillon C; Graham S; Grüschow S; White MF
    Nature; 2018 Oct; 562(7726):277-280. PubMed ID: 30232454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity.
    Athukoralage JS; McMahon SA; Zhang C; Grüschow S; Graham S; Krupovic M; Whitaker RJ; Gloster TM; White MF
    Nature; 2020 Jan; 577(7791):572-575. PubMed ID: 31942067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of the cyclic oligoadenylate signaling pathway of type III CRISPR systems.
    Rouillon C; Athukoralage JS; Graham S; Grüschow S; White MF
    Methods Enzymol; 2019; 616():191-218. PubMed ID: 30691643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate selectivity and catalytic activation of the type III CRISPR ancillary nuclease Can2.
    Jungfer K; Sigg A; Jinek M
    Nucleic Acids Res; 2024 Jan; 52(1):462-473. PubMed ID: 38033326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatic analysis of type III CRISPR systems reveals key properties and new effector families.
    Hoikkala V; Graham S; White MF
    Nucleic Acids Res; 2024 Jul; 52(12):7129-7141. PubMed ID: 38808661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Type III CRISPR-Cas: beyond the Cas10 effector complex.
    Stella G; Marraffini L
    Trends Biochem Sci; 2024 Jan; 49(1):28-37. PubMed ID: 37949766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Type III-B Cmr effector complex catalyzes the synthesis of cyclic oligoadenylate second messengers by cooperative substrate binding.
    Han W; Stella S; Zhang Y; Guo T; Sulek K; Peng-Lundgren L; Montoya G; She Q
    Nucleic Acids Res; 2018 Nov; 46(19):10319-10330. PubMed ID: 30239876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures of an active type III-A CRISPR effector complex.
    Smith EM; Ferrell S; Tokars VL; Mondragón A
    Structure; 2022 Aug; 30(8):1109-1128.e6. PubMed ID: 35714601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6.
    Garcia-Doval C; Schwede F; Berk C; Rostøl JT; Niewoehner O; Tejero O; Hall J; Marraffini LA; Jinek M
    Nat Commun; 2020 Mar; 11(1):1596. PubMed ID: 32221291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclic oligoadenylate signalling mediates Mycobacterium tuberculosis CRISPR defence.
    Grüschow S; Athukoralage JS; Graham S; Hoogeboom T; White MF
    Nucleic Acids Res; 2019 Sep; 47(17):9259-9270. PubMed ID: 31392987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of Cas10 Govern Discrimination between Self and Non-self in Type III CRISPR-Cas Immunity.
    Wang L; Mo CY; Wasserman MR; Rostøl JT; Marraffini LA; Liu S
    Mol Cell; 2019 Jan; 73(2):278-290.e4. PubMed ID: 30503774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Type III CRISPR-Cas systems produce cyclic oligoadenylate second messengers.
    Niewoehner O; Garcia-Doval C; Rostøl JT; Berk C; Schwede F; Bigler L; Hall J; Marraffini LA; Jinek M
    Nature; 2017 Aug; 548(7669):543-548. PubMed ID: 28722012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic oligoadenylate signalling and regulation by ring nucleases during type III CRISPR defence.
    Athukoralage JS; White MF
    RNA; 2021 May; 27(8):855-67. PubMed ID: 33986148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CRISPR effector Cam1 mediates membrane depolarization for phage defence.
    Baca CF; Yu Y; Rostøl JT; Majumder P; Patel DJ; Marraffini LA
    Nature; 2024 Jan; 625(7996):797-804. PubMed ID: 38200316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.